TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche received the decision from the European Commission confirming that Hemlibra ® (emicizumab) , a ...
Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or B ...
HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...
LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
Pfizer presents positive results from phase 3 BASIS study of Hympavzi in adults and adolescents with haemophilia A or B with inhibitors at ASH meeting: New York Tuesday, December ...
Marstacimab significantly reduced ABR by 93% vs on-demand treatment over 12 months. Topline data were announced from a phase 3 trial evaluating marstacimab for adults and adolescents living with ...
Hemophilia is a rare genetic condition that keeps your blood from clotting, leading to bleeding problems. Bleeding can happen at any time (spontaneous) or as a result of trauma (injury, cut, or fall).
Paris, June 21, 2024. Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place June 22-26, 2024, ...
People with severe hemophilia A are at risk for prolonged bleeding events that can cause serious complications. To prevent these bleeding events, most people with this condition get injections of a ...
Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback